Pulmonx Corporation
LUNG · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.9% | 5.9% | -5.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.7% | 72.1% | 72.5% | 74% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.4% | -58.3% | -64.6% | -55.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -64.9% | -63.6% | -64.1% | -55.4% |
| EPS Diluted | -0.34 | -0.38 | -0.36 | -0.33 |
| % Growth | 10.5% | -5.6% | -9.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |